AGP Executive Report
Last update: 11 hours agoHepatitis B Trial: Danish researchers are defending a proposed study involving 14,000 newborns in Guinea-Bissau, saying it will examine broader health outcomes. Under the plan, half the babies would receive the hepatitis B vaccine at birth and half at six weeks, the current practice. Researchers say a revised protocol has ethics approval in Denmark and Guinea-Bissau, but Health Minister Quinhin Nantote says the government has not authorized the trial. The dispute leaves the study’s status unclear, amid concerns about delaying a vaccine that protects against a disease linked to liver cancer and cirrhosis.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.